Pazopanib Versus Placebo in Women Without Progression After First-Line Chemotherapy for Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Aeoc): Second Interim Overall Survival Analysis from the Ago-Ovar16 Trial

Peritoneal Cancer ◽

AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5518 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5518-5518 ◽

Cited By ~ 4

Author(s):

Ignace Vergote ◽

Lars Christian Hanker ◽

Anne Floquet ◽

Joern Rau ◽

Jae-Weon Kim ◽

...

Keyword(s):

Overall Survival ◽

Fallopian Tube ◽

Phase Iii ◽

Efficacy And Safety ◽

First Line ◽

Peritoneal Cancer ◽

Phase Iii Study ◽

Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2020.05.004 ◽

2020 ◽

Vol 18 (6) ◽

pp. 452-460

Author(s):

Joaquim Bellmunt Molins ◽

Jesús García-Donas Jiménez ◽

Begoña P. Valderrama ◽

Juan Antonio Virizuela Echaburu ◽

Susana Hernando-Polo ◽

...

Keyword(s):

Overall Survival ◽

Survival Analysis ◽

Supportive Care ◽

Urothelial Carcinoma ◽

Best Supportive Care ◽

Phase 2 ◽

First Line ◽

Advanced Urothelial Carcinoma ◽

8033 Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71555-1 ◽

2009 ◽

Vol 7 (2) ◽

pp. 459

Author(s):

S. Nishio ◽

N. Katsumata ◽

K. Matsumoto ◽

H. Tanabe ◽

K. Yonemori ◽

...

Keyword(s):

Fallopian Tube ◽

First Line ◽

Peritoneal Cancer ◽

First Line Therapy ◽

Line Therapy ◽

Third Line ◽

Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-008-0488-x ◽

2008 ◽

Vol 135 (4) ◽

pp. 551-557 ◽

Cited By ~ 12

Author(s):

Shin Nishio ◽

Noriyuki Katsumata ◽

Koji Matsumoto ◽

Hiroshi Tanabe ◽

Kan Yonemori ◽

...

Keyword(s):

Fallopian Tube ◽

First Line ◽

Peritoneal Cancer ◽

First Line Therapy ◽

Line Therapy ◽

Third Line ◽

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

Annals of Oncology ◽

10.1093/annonc/mdz394.076 ◽

2019 ◽

Vol 30 ◽

pp. v914-v915 ◽

Cited By ~ 16

Author(s):

S.S. Ramalingam ◽

J.E. Gray ◽

Y. Ohe ◽

B.C. Cho ◽

J. Vansteenkiste ◽

...

Keyword(s):

Overall Survival ◽

Survival Analysis ◽

Advanced Nsclc ◽

Line Treatment ◽

First Line ◽

Egfr Tki ◽

First Line Treatment

Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.03.027 ◽

2012 ◽

Vol 125 (3) ◽

pp. 621-624 ◽

Cited By ~ 33

Author(s):

Joyce N. Barlin ◽

Fanny Dao ◽

Nadim Bou Zgheib ◽

Sarah E. Ferguson ◽

Paul J. Sabbatini ◽

...

Keyword(s):

Overall Survival ◽

Fallopian Tube ◽

Peritoneal Cancer

Overall survival analysis of the FOXFIRE-SIRFLOX-FOXFIRE global prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer

Annals of Oncology ◽

10.1093/annonc/mdx262.026 ◽

2017 ◽

Vol 28 ◽

pp. iii148

Author(s):

Harpreet Wasan ◽

Guy van Hazel ◽

Volker Heinemann ◽

Navesh Sharma ◽

Julien Taieb ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Liver Metastases ◽

First Line ◽

Selective Internal Radiotherapy ◽

Internal Radiotherapy ◽

Randomized Studies ◽

Overall Survival Analysis

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

Annals of Oncology ◽

10.1093/annonc/mdz446.015 ◽

2019 ◽

Vol 30 ◽

pp. ix198-ix199

Author(s):

B.C. Cho ◽

Y. Ohe ◽

C. Zhou ◽

T. Reungwetwattana ◽

Y. Cheng ◽

...

Keyword(s):

Overall Survival ◽

Survival Analysis ◽

Advanced Nsclc ◽

Line Treatment ◽

First Line ◽

Egfr Tki ◽

First Line Treatment

P-278 A phase II study of cetuximab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer (CIRIS study): overall survival analysis

Annals of Oncology ◽

10.1093/annonc/mdv233.275 ◽

2015 ◽

Vol 26 ◽

pp. iv82

Author(s):

T. Eto ◽

T. Masuishi ◽

T. Matsui ◽

S. Anzai ◽

Y. Suzuki ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Metastatic Colorectal Cancer ◽

Phase Ii Study ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

First Line Treatment

An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer

Annals of Translational Medicine ◽

10.21037/atm.2019.03.09 ◽

2019 ◽

Vol 7 (S1) ◽

pp. S53-S53

Author(s):

Muhammad Zubair Afzal ◽

Konstantin H. Dragnev ◽

Keisuke Shirai

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Overall Survival Analysis